Please login to the form below

Not currently logged in
Email:
Password:

Provenge improves survival

The Phase 3 trial of Provenge in men with advanced prostate cancer has reached its primary endpoint of improving overall survival

The Phase 3 trial of Provenge (sipuleucel-T) in men with advanced prostate cancer has reached its primary endpoint of improving overall survival compared to placebo. 

The IMPACT (Immunotherapy for Prostate Adenocarcinoma Treatment) study of 512 patients with metastatic androgen-independent prostate cancer was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. 

Seattle-based manufacturer Dendreon, intends to file an amendment to its Biologic License Application (BLA) for Provenge later this year. The FDA had requested additional clinical data in support of the efficacy claim.

There are limited treatment options for men with advanced, metastatic prostate cancer when the disease no longer responds to hormone blockers. Provenge could herald a new class of drugs, known as active cellular immunotherapies, which stimulate the immune system to fight cancer. It is produced from a patient's own cells and is sometimes referred to as a vaccine.

In a conference call earlier today Mitchell Gold, president and chief executive officer at Dendreon said that the results were an "unambiguous hit".

"The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient's own cancer," said Gold.

Detailed results from the IMPACT study will be presented on April 28 at the American Urological Association's Annual Meeting in Chicago.

14th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics